Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Receivables (2016 - 2017)

Northwest Biotherapeutics (NWBO) has 4 years of Receivables data on record, last reported at $3.8 million in Q4 2017.

  • For Q4 2017, Receivables changed 0.0% year-over-year to $3.8 million; the TTM value through Dec 2017 reached $3.8 million, changed 0.0%, while the annual FY2017 figure was $3.8 million, 0.0% changed from the prior year.
  • Receivables reached $3.8 million in Q4 2017 per NWBO's latest filing, roughly flat from $3.8 million in the prior quarter.
  • Across five years, Receivables topped out at $3.8 million in Q4 2016 and bottomed at $3.8 million in Q4 2016.